Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.
The company’s strategic focus remains centered on bexobrutinib, its potent BTK degrader.
Nurix confirmed that the ongoing Phase 2 DAYBreak CLL-201 study is progressing as planned, with data intended to support a potential pathway for Accelerated Approval in patients with chronic lymphocytic leukemia (CLL).
Building on this momentum, the company announced it is on track to initiate a global Phase 3 trial, DAYBreak CLL-306, by midyear 2026.
In addition to its oncology pipeline, Nurix is expanding its reach into the immunology sector.
The company set a formal 2026 target for an Investigational New Drug (IND) submission for a tablet formulation of bexobrutinib specifically optimized for immunological indications.
This expansion reflects the broad therapeutic potential of targeted protein degradation beyond traditional hematologic malignancies.
Financially, Nurix reported revenue of $6.3 million for the quarter ended February 28, 2026, primarily derived from its ongoing strategic collaborations with major pharmaceutical partners.
Research and development (R&D) expenses stood at $84.1 million, reflecting the intensive investment required for its late-stage clinical transitions and manufacturing scale-up.
The company also reported a net loss of $87.2 million for the quarter.
However, its balance sheet remains robust, with $540.7 million in cash, cash equivalents, and marketable securities.
Management noted that this liquidity provides a multi-year runway, extending well into 2028 and covering the anticipated completion of the primary endpoints for the upcoming Phase 3 CLL trial.